Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine"
DOI: 10.2169/internalmedicine.8392-21
Abstract: Objective Dasatinib, a second-generation tyrosine kinase inhibitor, is used for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It reportedly causes pulmonary arterial hypertension (PAH) and the dose-dependent induction of apoptosis… read more here.
Keywords: dasatinib induced; hypertension; relationship dasatinib; drug dose ... See more keywords